Drug Delivery

Regeneron to supply 1.4 million additional REGEN-COV doses to US

The US Department of Health and Human Services (HHS) and the Department of Defense (DOD) have signed an agreement with Regeneron Pharmaceuticals to buy additional doses of the firm’s Covid-19 antibody cocktail, REGEN-COV (casirivimab and imdevimab).

European Commission signs deal to buy 200 million doses of Novavax’ Covid-19 vaccine

The European Commission has finalised an advanced purchase agreement (APA) with Novavax to buy up to 200 million doses of NVX-CoV2373, the company’s Covid-19 vaccine candidate.

GSK and Vir Biotechnology to supply Covid-19 drug to EU

GlaxoSmithKline (GSK) and Vir Biotechnology have announced a joint procurement agreement with the European Commission for the supply of up to 220,000 doses of sotrovimab to treat Covid-19 patients.

European Commission buys additional doses of Moderna’s Covid-19 vaccine

The European Commission has purchased an additional 150 million Moderna’s Covid-19 vaccine doses, bringing its confirmed order commitment to 460 million doses.

AstraZeneca receives Belgium court orders to deliver 50 million vaccine doses to EU

Court of First Instance of Brussels has ordered AstraZeneca to deliver 50 million doses of its Covid-19 vaccine to Europe by 27 September this year.

Merck to supply 1.7 million courses of molnupiravir to US

Merck, called MSD outside the US and Canada, has signed an agreement with the US government to supply about 1.7 million courses of molnupiravir (MK-4482) for the treatment of mild to moderate Covid-19.

Carlyle Group to acquire pharma firm Vectura for $1.4bn

Private equity firm Carlyle Group’s subsidiary Murano Bidco has agreed to acquire British pharmaceutical company Vectura Group for about $1.4bn (£958m).

CD&R agrees to acquire UDG Healthcare for $3.7bn

Clayton, Dubilier & Rice (CD&R), a private investment firm, has signed an agreement to acquire London-listed UDG Healthcare for £2.6bn ($3.7bn).

GSK and Vir announce EMA review of VIR-7831 for early treatment of Covid-19

GlaxoSmithKline and Vir Biotechnology have announced the European Medicines Agency (EMA) review of VIR-7831 (GSK4182136) for the early treatment of Covid-19.